A synthetic fragment related to thymosin beta-4, studied for cell migration, actin regulation, and tissue-repair pathways.
Pre-loaded with a typical TB-500 vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for TB-500. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 2 mg – 5 mg | twice weekly | subcutaneous | Commonly cited in research-protocol summaries for synthetic TB-500 Frequently described loading-style ranges in secondary research summaries; not a standardized clinical regimen. |
| 2 mg – 2.5 mg | once weekly | subcutaneous | Maintenance-style ranges reported in research-community protocols Lower once-weekly figures often appear after an initial higher-frequency phase in informal protocol write-ups. |
| 42 mg – 1260 mg | single or daily multi-dose cohorts | intravenous | Human intravenous Tβ4 safety study (full-length peptide, not TB-500 fragment) Ruff et al. evaluated much higher IV Tβ4 exposures in healthy volunteers for safety/PK; this is not a TB-500 fragment dosing guide. |
People searching this page also look for: tb 500 peptide dosage, tb-500 peptide dosage, tb 500 peptide dosage chart, tb-500 peptide typical dosage per week, tb-500 peptide dosage protocol, peptide tb 500 dosage.
TB-500 is a synthetic research peptide associated with the actin-binding region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide abundant in platelets and wound fluid. In laboratory and preclinical models, Tβ4 and related fragments have been examined for roles in cell motility, angiogenesis, inflammation resolution, and extracellular-matrix organization after injury.
Researchers study TB-500 because full-length Tβ4 has a long experimental record in dermal wound models, cardiac injury paradigms, corneal repair work, and regenerative-biology reviews. The synthetic fragment is used as a more practical research tool when investigators want to probe actin-cytoskeleton and repair-associated signaling without working with the entire native protein.
All material discussed here is Research Use Only (RUO). It is not a drug product, not approved by the FDA for human use, and not intended for human consumption, clinical treatment, or diagnostic procedures. Published dosage figures below are literature or commonly cited research-protocol references, not recommendations.
Thymosin beta-4 sequesters G-actin and helps regulate actin polymerization, which influences cytoskeletal remodeling and cell migration. Related domains have been linked in the literature to pro-angiogenic signaling, reduced inflammatory tone at injury sites, and shifts in fibrosis-related cell phenotypes. TB-500 is studied as a compact surrogate for key actin-binding and repair-associated activities of the parent peptide, though fragment-versus-full-length differences remain an active research question.
tissue repair and wound models · cell migration and actin dynamics · angiogenesis · cardiac injury models · anti-fibrotic and inflammation-resolution pathways
Interest is highest among regenerative-biology, sports-medicine research, and wound-healing laboratories that model soft-tissue injury, angiogenesis, or cytoskeletal control of repair. Comparative work also appears in cardiac and corneal injury literature focused on Tβ4 biology rather than TB-500 as a clinical agent.
Keep lyophilized vials refrigerated or frozen, protected from light and moisture. After reconstitution with bacteriostatic water, refrigerate and use within the timeframe specified by the laboratory protocol, typically days to a few weeks.
In research discussions, TB-500 is frequently examined alongside BPC-157 because both appear in soft-tissue repair literature, though through different proposed pathways. Some protocols also pair actin-repair work with growth-hormone secretagogue or GHRH-analog models when the experimental question involves recovery physiology rather than a single molecular target.
The questions people actually search for, answered plainly.
Secondary research summaries most often cite about 2,000-5,000 mcg twice weekly during higher-intensity phases, with lower once-weekly amounts afterward. These are reference figures from protocol literature, not medical advice.
Not exactly. TB-500 is a synthetic peptide related to the actin-binding region of thymosin beta-4. Full-length Tβ4 is the native 43-amino-acid peptide used in many primary papers.
Research vials of 5-10 mg are commonly reconstituted with 2-3 mL bacteriostatic water so insulin-syringe graduations map cleanly to mcg amounts. Exact solvent volume depends on the assay design.
Most interest centers on actin sequestration, cell migration, angiogenesis, and inflammation-resolution signaling observed with Tβ4-family peptides in injury models.
No. Research-grade TB-500 is sold for laboratory Research Use Only. It is not an FDA-approved drug and is not for human consumption or clinical treatment.
Lyophilized material is usually kept cold and dry. After reconstitution, refrigerate and avoid repeated freeze-thaw cycles unless the protocol specifically calls for aliquots.
Primary animal studies often scale by body weight, whereas many secondary peptide-protocol charts use fixed absolute amounts. They are different reference frames and should not be mixed casually.
Primary literature on TB-500. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides